Want to see HK:2171 full AI Analyst Report?
Total Valuation
CARsgen Therapeutics Holdings Ltd. has a market cap or net worth of HK$8.90B. The enterprise value is HK$6.59B.
Market CapHK$8.90B
Enterprise ValueHK$6.59B
Share Statistics
CARsgen Therapeutics Holdings Ltd. has 601,455,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding601,455,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CARsgen Therapeutics Holdings Ltd.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -9.36%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-9.36%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee353.98K
Profits Per Employee-289.88K
Employee Count355
Asset Turnover0.10
Inventory Turnover6.40
Valuation Ratios
The current PE Ratio of CARsgen Therapeutics Holdings Ltd. is ―. CARsgen Therapeutics Holdings Ltd.’s PEG ratio is 0.85.
PE Ratio―
PS Ratio58.60
PB Ratio9.40
Price to Fair Value9.40
Price to FCF-30.30
Price to Operating Cash Flow-29.12
PEG Ratio0.85
Income Statement
In the last 12 months, CARsgen Therapeutics Holdings Ltd. had revenue of 125.66M and earned -97.86M in profits. Earnings per share was -0.18.
Revenue125.66M
Gross Profit79.95M
Operating Income-104.21M
Pretax Income-102.91M
Net Income-97.86M
EBITDA-203.91M
Earnings Per Share (EPS)-0.18
Cash Flow
In the last 12 months, operating cash flow was -253.97M and capital expenditures 45.29M, giving a free cash flow of -262.35M billion.
Operating Cash Flow-253.97M
Free Cash Flow-262.35M
Free Cash Flow per Share-0.44
Dividends & Yields
CARsgen Therapeutics Holdings Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-27.28%
50-Day Moving Average17.76
200-Day Moving Average17.19
Relative Strength Index (RSI)43.11
Average Volume (3m)1.98M
Important Dates
CARsgen Therapeutics Holdings Ltd. upcoming earnings date is Aug 25, 2026, TBA (Confirmed).
Last Earnings DateMar 6, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date―
Financial Position
CARsgen Therapeutics Holdings Ltd. as a current ratio of 5.73, with Debt / Equity ratio of 7.81%
Current Ratio5.73
Quick Ratio5.70
Debt to Market Cap<0.01
Net Debt to EBITDA5.21
Interest Coverage Ratio-15.11
Taxes
In the past 12 months, CARsgen Therapeutics Holdings Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CARsgen Therapeutics Holdings Ltd. EV to EBITDA ratio is -30.90, with an EV/FCF ratio of -25.93.
EV to Sales50.14
EV to EBITDA-30.90
EV to Free Cash Flow-25.93
EV to Operating Cash Flow-27.58
Balance Sheet
CARsgen Therapeutics Holdings Ltd. has HK$1.12B in cash and marketable securities with HK$61.20M in debt, giving a net cash position of HK$1.06B billion.
Cash & Marketable SecuritiesHK$1.12B
Total DebtHK$61.20M
Net CashHK$1.06B
Net Cash Per ShareHK$1.77
Tangible Book Value Per ShareHK$1.41
Margins
Gross margin is 63.62%, with operating margin of -82.93%, and net profit margin of -77.88%.
Gross Margin63.62%
Operating Margin-82.93%
Pretax Margin-81.89%
Net Profit Margin-77.88%
EBITDA Margin-162.27%
EBIT Margin-181.36%
Analyst Forecast
The average price target for CARsgen Therapeutics Holdings Ltd. is HK$25.70, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$25.70
Price Target Upside72.60% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast219.26%
EPS Growth Forecast87.63%